The latest price target for Ascendis Pharma (NASDAQ:ASND) was reported by UBS on January 7, 2025. The analyst firm set a price target for $196.00 expecting ASND to rise to within 12 months (a possible 53.44% upside). 42 analyst firms have reported ratings in the last year.

The latest analyst rating for Ascendis Pharma (NASDAQ:ASND) was provided by UBS, and Ascendis Pharma initiated their buy rating.

The last upgrade for Ascendis Pharma AS happened on September 5, 2024 when Oppenheimer raised their price target to $180. Oppenheimer previously had a perform for Ascendis Pharma AS.

The last downgrade for Ascendis Pharma AS happened on April 5, 2023 when Oppenheimer changed their price target from N/A to N/A for Ascendis Pharma AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ascendis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ascendis Pharma was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.

While ratings are subjective and will change, the latest Ascendis Pharma (ASND) rating was a initiated with a price target of $0.00 to $196.00. The current price Ascendis Pharma (ASND) is trading at is $127.74, which is within the analyst’s predicted range.